{"id":"W4400240704","doi":"10.4103/iju.iju_62_24","title":"Combination therapy for advanced urothelial cancer: LEAP-011 trial","year":2024,"lang":"en","type":"article","venue":"Indian Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Hazard ratio; Placebo; Adverse effect; Oncology; Randomized controlled trial; Confidence interval; Cancer; Sorafenib; Immunotherapy; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001938593,0.0007831126,0.001941932,0.0003682272,0.0003536248,0.001086773,0.0008627212,0.001246505,0.006353412],"category_scores_gemma":[0.001407971,0.0003134511,0.001616992,0.0004684297,0.0004656847,0.001130192,0.0006023613,0.003812764,0.0009582224],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006471197,"about_ca_system_score_gemma":0.0006263496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000312778,"about_ca_topic_score_gemma":0.0006719112,"domain_scores_codex":[0.9992408,0.0004584905,0.00003758121,0.0001278515,0.0000742193,0.00006113474],"domain_scores_gemma":[0.9992054,0.0002110687,0.0002001085,0.00005795754,0.00004653343,0.0002789111],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7895552,0.007064916,0.004354702,0.004990972,0.005075792,0.0003360914,0.0001219485,0.002560071,0.006192354,0.001078576,0.01663668,0.1620327],"study_design_scores_gemma":[0.8760079,0.09759904,0.006700172,0.0004328533,0.002545891,0.0005120379,0.00004707993,0.001816776,0.001046079,0.0007315581,0.01251249,0.00004822858],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9057218,0.06788594,0.001668374,0.005798636,0.000937624,0.002416519,0.004727972,0.0003231856,0.0105199],"genre_scores_gemma":[0.9661644,0.01307491,0.002257347,0.003984937,0.0008287943,0.003539217,0.00425301,0.0000472437,0.00585024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006353412,"threshold_uncertainty_score":0.02125424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02451463644948239,"score_gpt":0.3369613821673754,"score_spread":0.312446745717893,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}